TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
2.73 ^USD	+0.74%		-8.08%	-61.11%

Apr. 30	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	MT
Apr. 29	TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	CI

TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 04:02 pm EDT

TFF Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 21.24 million compared to USD 31.77 million a year ago. Basic loss per share from continuing operations was USD 11.85 compared to USD 26.49 a year ago.

Latest news about TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	Apr. 30	MT
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	Apr. 29	CI
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	Apr. 15	CI
TFF Pharmaceuticals Files Equities Shelf	Apr. 08	MT
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	Mar. 28	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating	Mar. 28	MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call	Mar. 27
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	Mar. 27	CI
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	Mar. 20	MT
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	Mar. 20	CI
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	Jan. 24	CI
Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	Dec. 30	CI
Certain Options of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	Dec. 30	CI
Certain Common Stock of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	Dec. 30	CI
Transcript : TFF Pharmaceuticals, Inc. - Special Call	Dec. 19
TFF Pharmaceuticals, Inc. Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	Dec. 19	CI
TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors	Dec. 13	CI
TFF Pharmaceuticals, Inc. Appoints Michael Patane to its Board of Directors and Compensation Committee	Nov. 30	CI
TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors and Nominating & Corporate Governance Committee	Nov. 30	CI
TFF Pharmaceuticals Files $100 Million Mixed Shelf	Nov. 22	MT
Transcript : TFF Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board	23-09-18	CI

Chart TFF Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for TFF Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.73 USD

Average target price

36 USD

Spread / Average Target

+1,218.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TFF PHARMACEUTICALS, INC.	-61.11%	6.88M
IQVIA HOLDINGS INC.	+0.17%	42.19B
MODERNA, INC.	+10.92%	42.24B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B

Other Biotechnology & Medical Research